We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Semaglutide (GLP-1 receptor agonist)
An FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Prescription medication — not a dietary supplement
Semaglutide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Semaglutide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2016–2026 with a typical study size of 782 participants.
Based on 339 studies · 101 meta-analyses · 209 RCTs · 107,002 total participants
Confidence
High confidenceBy outcome
An FDA-approved drug with one of the strongest evidence bases here: multiple large phase-3 RCTs (STEP, SUSTAIN, SELECT) prove substantial weight loss, glycemic control, and reduced cardiovascular events.
416 rigorous studies
247 randomized trials · 135 meta-analyses · 34 systematic reviews
Our evidence rating for Semaglutide is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
339 trials ongoing or recruiting · 329 completed on ClinicalTrials.gov
97 of the completed trials have posted results
Registered trials show research momentum for Semaglutide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Semaglutide is a long-acting analogue of the gut hormone GLP-1 (glucagon-like peptide-1).
It is a prescription drug, NOT a dietary supplement: branded as Ozempic (subcutaneous, type 2 diabetes), Rybelsus (oral, type 2 diabetes), and Wegovy (subcutaneous, chronic weight management), and approved by the FDA for these indications, with an additional indication to reduce cardiovascular risk in adults with established cardiovascular disease and either type 2 diabetes or overweight/obesity.
Mechanistically it activates the GLP-1 receptor in the pancreas (glucose-dependent insulin secretion, suppressed glucagon), brain (appetite suppression and satiety), and gut (slowed gastric emptying).
The evidence base is one of the strongest of any entry on this site: multiple large phase-3 randomized controlled trials. In type 2 diabetes, SUSTAIN-6 (3,297 patients) showed a 26% relative reduction in major adverse cardiovascular events (HR 0.74) and head-to-head SUSTAIN 7 beat dulaglutide on both HbA1c and weight.
For weight management, STEP 1 (1,961 adults without diabetes) produced a mean −14.9% body-weight change vs −2.4% on placebo at 68 weeks, with over half losing ≥15%; STEP 8 showed it substantially out-loses liraglutide.
SELECT (17,604 patients with cardiovascular disease and overweight/obesity but WITHOUT diabetes) showed a 20% relative reduction in cardiovascular death, MI, or stroke (HR 0.80). Oral semaglutide (PIONEER program) reproduces glycemic benefit and was cardiovascular-non-inferior in PIONEER 6.
The honest counterweight: semaglutide carries a boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma) and is contraindicated with a personal/family history of medullary thyroid carcinoma or MEN2; it carries risks of pancreatitis, gallbladder disease, and ileus; gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common; weight loss includes loss of lean muscle; and the FDA has warned about dosing errors and impurities in compounded/grey-market semaglutide.
It should be used only under a clinician's care, for a genuine medical indication — not as a cosmetic shortcut.
A long-acting analogue of the incretin hormone GLP-1 that binds and activates the GLP-1 receptor in the pancreas, brain, and gastrointestinal tract — the single upstream target driving all downstream effects.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk.
Acts on central appetite-regulating circuits to increase satiety and reduce food intake, the primary driver of the substantial weight loss seen in the STEP trials.
Delays gastric emptying, blunting post-meal glucose excursions and prolonging fullness — and the mechanism behind much of the nausea and the ileus signal.
How Semaglutide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated — boxed warning for thyroid C-cell tumors.
Use with caution under specialist guidance; generally avoid with prior pancreatitis.
Contraindicated — discontinue at least 2 months before a planned pregnancy.
Not appropriate — this is a prescription drug with real risks, not a cosmetic shortcut. Use only for a clinician-confirmed indication.
Combining with insulin or sulfonylureas raises hypoglycemia risk; the clinician typically reduces those agents. Semaglutide alone is low-hypoglycemia (glucose-dependent action).
Delayed gastric emptying can change the absorption of co-administered oral drugs; clinician monitoring advised, especially for narrow-therapeutic-index medicines.
Do not combine with another GLP-1 agonist (e.g. liraglutide, dulaglutide, tirzepatide) — additive risk with no added benefit.
Tip: Gradual dose titration; smaller meals; usually transient as the body adapts
Tip: Slow titration, hydration, dietary adjustment; report severe/persistent symptoms to a clinician
Tip: Seek care for upper-right abdominal pain, fever, or jaundice
Tip: Discontinue and seek urgent care for severe, persistent abdominal pain radiating to the back
Tip: Post-marketing reports; seek care for severe constipation, bloating, or inability to pass stool/gas
Tip: Resistance training and adequate protein intake during weight loss
Tip: Linked to rapid glucose lowering (SUSTAIN-6); patients with diabetic retinopathy need ophthalmologic monitoring
Semaglutide has an evidence score of 8.5/10 — very strong evidence based on 312 indexed studies, including 2 meta-analyses. An FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended. Representative study: PMID 34047443.
The commonly studied dose of Semaglutide is Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Semaglutide — consistent daily use matters more than the time of day. Subcutaneous dosing is once weekly on the same day, with or without food.
Semaglutide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea, vomiting / diarrhea / constipation, gallbladder disease (cholelithiasis / cholecystitis). Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN2); Prior serious hypersensitivity to semaglutide or any GLP-1 receptor agonist.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Mostly mechanism / observationalAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. Included here for reference only; it is NOT a supplement and is not auto-recommended.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Dulaglutide
Mostly mechanism / observationalAn FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is included here for reference only, not as a supplement and not auto-recommended.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 339 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research